[
  {
    "id": "NCLEX-2026-MISSION-500-6-1771959816003",
    "version": "1.0",
    "type": "standalone",
    "stem": "The nurse is caring for a 72-year-old client admitted with deep vein thrombosis (DVT) and prescribed heparin and warfarin. Review the client's EHR and complete the tasks that follow.",
    "format": "graphic",
    "category": "pharmacology",
    "subcategory": "anticoagulation",
    "topic": "Heparin/Warfarin Anticoagulation Safety",
    "patient": {
      "age": 72,
      "gender": "male",
      "medicalHistory": [
        "Deep Vein Thrombosis (DVT)",
        "Atrial Fibrillation",
        "Hypertension"
      ],
      "currentMedications": [
        "Heparin 5000 units SubQ q12h",
        "Warfarin 5mg PO daily",
        "Metoprolol 25mg PO BID",
        "Lisinopril 10mg PO daily"
      ]
    },
    "itemContext": {
      "SBAR": "14:00. Situation: Mr. Johnson, 72-year-old male, admitted for DVT. Background: History of atrial fibrillation, hypertension. Currently on heparin 5000 units SubQ q12h and warfarin 5mg PO daily, started 3 days ago. Assessment: Client reports mild leg pain (3/10) and slight swelling in the affected leg. Vital signs: BP 130/80, HR 88 and irregular, RR 16, Temp 37.0Â°C. INR today is 1.3. No signs of active bleeding. Heparin was last administered at 08:00. Pt also takes metoprolol and lisinopril daily. Recommendation: INR is subtherapeutic, consider increasing warfarin dose. Monitor for signs of bleeding, especially given concurrent heparin and warfarin therapy. Repeat INR tomorrow morning. Continue current heparin regimen until INR is therapeutic.",
      "Labs": [
        {
          "name": "INR",
          "value": "1.3",
          "units": null,
          "date": "2024-01-30",
          "time": "14:00"
        },
        {
          "name": "PTT",
          "value": "35",
          "units": "seconds",
          "date": "2024-01-30",
          "time": "14:00"
        },
        {
          "name": "Platelets",
          "value": "250000",
          "units": "mm3",
          "date": "2024-01-30",
          "time": "14:00"
        },
        {
          "name": "Hemoglobin",
          "value": "14.5",
          "units": "g/dL",
          "date": "2024-01-30",
          "time": "14:00"
        }
      ],
      "Vitals": {
        "BP": "130/80",
        "HR": "88",
        "RR": "16",
        "Temp": "37.0",
        "SpO2": "98"
      },
      "Radiology": [],
      "MAR": [
        {
          "medication": "Heparin",
          "dosage": "5000 units",
          "route": "SubQ",
          "frequency": "q12h",
          "lastAdministered": "08:00",
          "nextDose": "20:00"
        },
        {
          "medication": "Warfarin",
          "dosage": "5mg",
          "route": "PO",
          "frequency": "daily",
          "lastAdministered": "09:00",
          "nextDose": "09:00"
        },
        {
          "medication": "Metoprolol",
          "dosage": "25mg",
          "route": "PO",
          "frequency": "BID",
          "lastAdministered": "08:00",
          "nextDose": "20:00"
        },
        {
          "medication": "Lisinopril",
          "dosage": "10mg",
          "route": "PO",
          "frequency": "daily",
          "lastAdministered": "09:00",
          "nextDose": "09:00"
        }
      ]
    },
    "tasks": [
      {
        "title": "Medication Safety Concerns",
        "type": "SATA",
        "stem": "Based on the client's current status and medication regimen, identify potential safety concerns that the nurse should address.",
        "options": [
          {
            "id": "option1",
            "text": "Increased risk of bleeding due to concurrent heparin and warfarin therapy.",
            "correct": true,
            "rationale": "The client is at an increased risk of bleeding due to the synergistic anticoagulant effects of heparin and warfarin, especially before the INR reaches a therapeutic range. Close monitoring for bleeding is essential."
          },
          {
            "id": "option2",
            "text": "Potential for heparin-induced thrombocytopenia (HIT).",
            "correct": false,
            "rationale": "While HIT is a risk with heparin therapy, the platelet count is within normal limits, making this less likely at this time. Monitor platelets."
          },
          {
            "id": "option3",
            "text": "Subtherapeutic INR indicating inadequate anticoagulation.",
            "correct": true,
            "rationale": "The INR of 1.3 is subtherapeutic, indicating that the warfarin dosage may need adjustment to achieve adequate anticoagulation and prevent further thrombotic events. The therapeutic range for warfarin is generally 2.0-3.0."
          },
          {
            "id": "option4",
            "text": "Hypotension related to lisinopril.",
            "correct": false,
            "rationale": "The client's BP of 130/80 is within acceptable parameters. While lisinopril can cause hypotension, there is no indication that it is currently a concern."
          },
          {
            "id": "option5",
            "text": "Risk of atrial fibrillation-related thromboembolic events.",
            "correct": true,
            "rationale": "The client's history of atrial fibrillation increases the risk of thromboembolic events. The subtherapeutic INR further elevates this risk, necessitating careful monitoring and possible warfarin dosage adjustment."
          },
          {
            "id": "option6",
            "text": "Bradycardia related to metoprolol.",
            "correct": false,
            "rationale": "The client's heart rate of 88 is within normal limits. While metoprolol can cause bradycardia, there is no indication that it is currently a concern."
          }
        ],
        "scoringRule": "polytomous"
      },
      {
        "title": "Prioritize Nursing Actions",
        "type": "bowtie",
        "stem": "Based on the identified safety concerns, use the Bowtie Model to prioritize the nurse's actions.",
        "options": {
          "condition": [
            {
              "id": "condition1",
              "text": "Subtherapeutic INR (1.3)"
            },
            {
              "id": "condition2",
              "text": "Increased risk of bleeding"
            }
          ],
          "action": [
            {
              "id": "action1",
              "text": "Administer Vitamin K"
            },
            {
              "id": "action2",
              "text": "Hold the next dose of heparin"
            },
            {
              "id": "action3",
              "text": "Monitor for signs of bleeding"
            },
            {
              "id": "action4",
              "text": "Contact the provider to increase warfarin dose"
            },
            {
              "id": "action5",
              "text": "Reassure patient that INR will increase on its own"
            }
          ],
          "outcome": [
            {
              "id": "outcome1",
              "text": "Reduced risk of thromboembolic events"
            },
            {
              "id": "outcome2",
              "text": "INR within therapeutic range (2.0-3.0)"
            },
            {
              "id": "outcome3",
              "text": "Absence of bleeding complications"
            }
          ]
        },
        "mapping": {
          "condition1": [
            "action4"
          ],
          "condition2": [
            "action3",
            "action2"
          ],
          "action4": [
            "outcome2"
          ],
          "action3": [
            "outcome3"
          ],
          "action2": [
            "outcome3"
          ]
        },
        "scoringRule": "linked"
      }
    ],
    "rationale": {
      "correct": "The client is at risk for both bleeding and thromboembolic events due to the concurrent use of heparin and warfarin, and a subtherapeutic INR. Heparin provides immediate anticoagulation while warfarin takes several days to reach therapeutic levels. An INR of 1.3 indicates that the warfarin is not yet providing adequate anticoagulation, increasing the risk of clot formation, especially given the client's history of DVT and atrial fibrillation. Contacting the provider to increase the warfarin dose is necessary to achieve a therapeutic INR and reduce the risk of thromboembolic complications. Monitoring for bleeding is crucial due to the synergistic effects of heparin and warfarin. Holding heparin may be necessary if signs of bleeding occur. Vitamin K is not immediately indicated, as it would reverse the effects of warfarin and is typically reserved for cases of significant over-anticoagulation or bleeding. Reassuring the patient that the INR will increase on its own is incorrect, as intervention is likely needed to adjust the warfarin dosage.",
      "incorrect": "",
      "clinicalPearls": [
        "Concurrent heparin and warfarin therapy requires careful monitoring of INR and signs of bleeding. Warfarin's effect is delayed, typically taking 3-5 days to reach therapeutic levels. Always consider the indication for anticoagulation when assessing safety and efficacy."
      ],
      "questionTrap": {
        "trap": "Focus Area",
        "howToOvercome": "Many students select options focusing solely on bleeding risk, overlooking the equally important risk of thromboembolic events due to the subtherapeutic INR. The concurrent use of heparin and warfarin often distracts test takers, causing them to focus only on bleeding risks."
      },
      "mnemonic": {
        "title": "HINT",
        "expansion": "W.A.R.F.A.R.I.N.: Watch for bleeding, Assess INR regularly, Risk of thromboembolism, Follow up with labs, Avoid Vitamin K-rich foods, Report unusual symptoms, Initiate heparin concurrently, Never abruptly stop."
      },
      "answerBreakdown": [],
      "reviewUnits": []
    },
    "clinicalPearls": "Concurrent heparin and warfarin therapy requires careful monitoring of INR and signs of bleeding. Warfarin's effect is delayed, typically taking 3-5 days to reach therapeutic levels. Always consider the indication for anticoagulation when assessing safety and efficacy.",
    "questionTrap": "Many students select options focusing solely on bleeding risk, overlooking the equally important risk of thromboembolic events due to the subtherapeutic INR. The concurrent use of heparin and warfarin often distracts test takers, causing them to focus only on bleeding risks.",
    "mnemonic": "W.A.R.F.A.R.I.N.: Watch for bleeding, Assess INR regularly, Risk of thromboembolism, Follow up with labs, Avoid Vitamin K-rich foods, Report unusual symptoms, Initiate heparin concurrently, Never abruptly stop.",
    "scoring": {
      "method": "polytomous",
      "maxPoints": 1
    },
    "pedagogy": {
      "bloomLevel": "apply",
      "cjmmStep": "analyzeCues",
      "nclexCategory": "Physiological Adaptation",
      "topicTags": [
        "Uncategorized"
      ],
      "difficulty": 5
    }
  }
]